SG/CALL/VERTEX PHARMACEUTICALS/320/0.1/17.01.25 | Market Closed - Deutsche Boerse AG 03:49:23 2024-07-11 pm EDT | ||
| 16.87 EUR | +0.06% |
|
| Current month | +9.47% | ||
| 1 month | +2.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 16.87 | +0.06% |
| 24-07-10 | 16.86 | +2.93% |
| 24-07-09 | 16.38 | +1.99% |
| 24-07-08 | 16.06 | +5.24% |
| 24-07-05 | 15.26 | +3.39% |
Delayed Quote Deutsche Boerse AG
Last update July 11, 2024 at 03:49 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SQ864U |
| ISIN | DE000SQ864U8 |
| Date issued | 2023-02-16 |
| Strike | 320 $ |
| Maturity | 2025-01-17 (190 Days) |
| Parity | 10 : 1 |
| Emission price | 5.69 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.03 € |
|---|---|
| Lowest since issue | 4.53 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
492.1
USD
Average target price
473.1
USD
Spread / Average Target
-3.87%
- Stock Market
- Warrants
- Warrant
